Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial tests the safety, side effects and best dose of sotorasib with trastuzumab deruxtecan and how well the combination works in treating patients with KRAS G12C mutated non-small cell lung cancer that has spread to nearby tissues or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). Sotorasib blocks a protein made by the mutated KRAS gene (KRAS p.G12C), which may help keep tumor cells from growing and may kill them. It is a type of targeted therapy. Trastuzumab deruxtecan is in a class of medications called antibody-drug conjugates. It is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Giving sotorasib in combination with trastuzumab deruxtecan may be safe, tolerable, and/or effective in treating patients with locally advanced or metastatic non-small cell lung cancer with a KRAS G12C mutation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjenci, u których zdiagnozowano zaawansowany lub rozsiany rak płuca z mutacją KRAS G12C, który był wcześniej leczony lekiem blokującym mutację KRAS G12C, lekiem wpływającym na układ odpornościowy oraz chemioterapią.
- •Mutacja KRAS G12C musi być potwierdzona w tkance guza lub we krwi.
- •Przed rozpoczęciem badania należy potwierdzić, jaki dokładnie lek blokujący mutację KRAS G12C był wcześniej stosowany i kiedy.
- •Muszą istnieć dane o ostatnim leczeniu, które otrzymał pacjent, i o tym, czy zawierało ono lek blokujący mutację KRAS G12C.
- •Muszą być dostępne informacje o wcześniejszym stanie HER2 guza.
- •Pacjenci muszą mieć obecność mutacji HER2.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Moffitt Cancer Center-International Plaza
Tampa, United States
Moffitt Cancer Center - McKinley Campus
Tampa, United States
Moffitt Cancer Center
Tampa, United States
Moffitt Cancer Center at Wesley Chapel
Wesley Chapel, United States
Case Western Reserve University
Cleveland, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
UPMC Hillman Cancer Center
Pittsburgh, United States
University of Virginia Cancer Center
Charlottesville, United States
Trial contact
Site Public Contact
Surbhi Singhal
PRINCIPAL_INVESTIGATOR
Site Public Contact
Andreas N. Saltos
PRINCIPAL_INVESTIGATOR
Site Public Contact
Matthew M. Mirsky
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jacob Kaufman
PRINCIPAL_INVESTIGATOR
Site Public Contact
Liza C. Villaruz
PRINCIPAL_INVESTIGATOR
Site Public Contact
Richard D. Hall
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.